INTERNATIONAL | U.S.
Careers
Contact Us
About us
Products
News, Press & Events
Login
Visit this section
Visit this section
Explore our news

Veryan Design Intelligence:
imagination + intuition + innovation

Our Vision

'We exist to improve patient care and quality of life through imagination, intuition and innovation'

 

Our Purpose

‘Transforming lives through design intelligence’

BioMimics-3D® Vascular Stent System

The BioMimics-3D Vascular Stent System has a unique 3D helical geometry which imparts a gentle helical shape to the stented artery.

Read more
MIMICS-2 3-year data released

Professor Thomas Zeller PI of the MIMICS-2 IDE study has announced that the freedom from CDTLR at 3 years for the BioMimics 3D stent was 81%, which is comparable to the outcomes for DCB, DES and Supera, despite treating more challenging lesions and without the need for lesion preparation.

Read more
Veryan & Otsuka

Veryan was founded in 2005 as the result of a technology spin out from Imperial College, London.

Read more

The Latest from Veryan

News, updates and press releases

BioMimics 3D® Vascular Stent System granted Good Design Award 2022

TOKYO, JAPAN – 07 OCTOBER 2022 – Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”, subsidiary of Otsuka Holdings Co., Ltd.) is pleased to announce that the BioMimics 3D Vascular Stent System has been granted a Good Design Award 2022 from the Japan Institute of Design Promotion.

Read more
Board Announcement – Appointment of new CEO

HORSHAM, UK – 01 SEPTEMBER 2022 – The Board of Veryan Holdings Ltd announces that, following 11 years of service, including 8 years as COO and 3 years as CEO, Nick Yeo has decided to leave Veryan to pursue new professional and personal goals.

Read more
MIMICS-3D EU 3-year results

Veryan Medical has confirmed the release at ISET 22 of the MIMICS-3D EU 3-year results by the study PI Michael Lichtenberg MD. MIMICS-3D EU is a prospective, multicentre, observational registry to evaluate the BioMimics 3D Vascular Stent System. The study evaluated safety, effectiveness and device performance within a real-world clinical population of 507 patients enrolled in 23 pan-European sites.

Read more

Get in touch

Find contact details and send us a message.

Contact us